Novartis exercises option to acquire IFM Due for $835m

14 Mar 2024
www.pharmaceutical-technology.com
AcquisitionImmunotherapy
Novartis exercises option to acquire IFM Due for $835m
Preview
Source: Pharmaceutical Technology
The collaboration between IFM Due and Novartis began in September 2019. Credit: lucarista / Shutterstock.com.
Novartis has exercised an option for the acquisition of all outstanding capital stock of IFM Therapeutics subsidiary IFM Due for $835m.
The strategic acquisition will grant Novartis the complete rights to IFM Due’s portfolio of STING antagonists, which address a range of serious inflammation-driven diseases.
IFM Due, established in February 2019, develops small molecule orally available drug candidates targeting the cyclic GMP-AMP synthase, a stimulator of the interferon genes (cGAS-STING) pathway, which is implicated in several serious diseases.
The collaboration between IFM Due and Novartis began in September 2019 when the companies made an option and partnership agreement.
Novartis agreed to fund research and development by IFM Due for the cGAS-STING programme in exchange for an option to acquire the company.
See Also:
Novartis files patent for combination therapy for b-cell lymphoma with CD19 car and BCL2 inhibitorBCL2 inhibitor
Novartis exercises option to acquire IFM Due for $835m
Preview
Source: Pharmaceutical Technology
Novartis exercises option to acquire IFM Due for $835m
Preview
Source: Pharmaceutical Technology
With the option exercised, IFM received an upfront payment of $90m from Novartis and is also entitled to milestone payments of $745m.
The acquisition is a significant move for Novartis, as it will secure complete rights for IFM Due’s portfolio comprising STING antagonists.
These assets have the potential to treat serious inflammation-driven ailments characterised by excessive interferon and other pro-inflammatory cytokine signalling.
The cGAS-STING pathway functions within the innate immune system to sense cytosolic DNA, a signal of cellular danger, and then triggers a STING-dependent inflammatory response.
Inappropriate activation of this pathway can result from genetic mutations or factors such as mitochondrial dysfunction, leading to diseases characterised by excessive inflammation.
Novartis immunology research global head Richard Siegel said: “The acquisition of IFM Due represents the culmination of a highly productive, four-year preclinical collaboration between Novartis and IFM to develop novel small-molecule STING inhibitorsSTING inhibitors with the potential to treat a spectrum of inflammatory diseases.
“We are excited to advance IFM Due’s STING programme and leverage our deep expertise in inflammation science to bring forward transformative medicines that address major unmet patient needs.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.